Experimental cell therapy for relapsed acute leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests an experimental cell therapy (called Hema-NeoTIL01) for people with acute leukemia that has come back or not responded to standard treatments. The therapy uses your own immune cells to try to attack and destroy the leukemia cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 69 years old.
- You must have acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).
- Your leukemia must have returned after treatment or not responded to standard treatments.
- If you have had CAR-T cell therapy before, it must have not worked or your cancer came back after it.
- You should feel well enough to care for yourself (ECOG score 2 or less).
- Your heart, liver, and kidney function must be within acceptable limits for this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new cell therapy called SNC116 for adults with a type of leukemia (B-cell acute lymphoblastic leukemia) that has come back or not responded to standard treatments. The therapy targets a protein called CD19 on the cancer cells to try to destroy them.
This trial tests a new type of immunotherapy called CAR-T cells, which are made from your own blood cells and trained to find and destroy leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
This trial tests a combination of two different engineered immune cell therapies to treat B-ALL (a leukemia). It’s designed for young people whose disease has come back, is hard to treat, or didn’t respond well to similar cell therapies.
This trial tests a new type of cell therapy that uses your own immune cells (T cells) that have been changed in the lab to find and attack leukemia cells that have a marker called CD84. It is for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
This trial tests an experimental cell therapy called CCTx-001 for people with acute myeloid leukemia that has not responded to standard treatments or has come back. The treatment involves collecting your own immune cells, engineering them, and giving them back to attack the leukemia.
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.